Richard Gonzalez, AP Images

Ab­b­Vie sees a megablock­buster in Vray­lar. Could a new de­pres­sion in­di­ca­tion push peak sales past $4B?

De­spite a bumpy take­off, Ab­b­Vie has some big plans for Vray­lar, the block­buster schiz­o­phre­nia and bipo­lar drug it snapped up from Al­ler­gan a cou­ple of years ago. Look­ing ahead, CEO Richard Gon­za­lez says a sup­ple­men­tal ap­proval in ma­jor de­pres­sive dis­or­der could send sales in­to the stratos­phere — that is, if the FDA is will­ing to get on board.

As promised in the re­cent Q4 call, Ab­b­Vie has sub­mit­ted its sN­DA fil­ing for Vray­lar as an add-on ther­a­py for MDD, one of the most com­mon men­tal dis­or­ders in the US. The com­pa­ny’s hop­ing for a reg­u­la­to­ry de­ci­sion by the end of the year — and if all goes well, Gon­za­lez says the in­di­ca­tion could push peak sales past the $4 bil­lion mark.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.